Crucell Teams up with ACE BioSciences and Harvard to Accelerate Bacterial Antibody Program LEIDEN, Netherlands, Nov. 02, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that it has licensed bacterial antigens from ACE BioSciences...

Galapagos Featured in Leading Drug Discovery Journal MECHELEN, Belgium, Oct. 14, 2005 (PRIMEZONE) -- Galapagos NV, a genomics-based drug discovery company, announces that an article presenting the Company's approach to target discovery will appear in...

Active Biotech: Confirmed ANYARA Tumor PET Localization in Cancer Patients STOCKHOLM, Sweden, Sept. 30, 2005 (PRIMEZONE) -- In an ongoing clinical Phase I study, specific tumor localization of Active Biotech's candidate drug ANYARA, has now been objectively confirmed.Using...

Crucell Appoints Agents to Boost Asian Market Potential LEIDEN, Netherlands, Sept. 20, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that it has entered into agreements with Pharma&Soft in...